Moderna and Aldevron announced expanded partnership for mRNA vaccine and therapeutic pipeline
On May 24, 2021, Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, the…
-
-
Study initiated exploring coadministration of 20-valent pneumococcal conjugate vaccine with third dose of Pfizer-BioNTech COVID-19 vaccine
On May 24, 2021, Pfizer announced that the first enrolled subjects had received their immunizations as part of…
-
Moderna and Samsung Biologics announced agreement for manufacturing of Moderna’s COVID-19 vaccine
On May 22, 2021, Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung…
-
Novavax announced MOU to explore expansion of COVID-19 vaccine activities in South Korea
On May 22, 2021, Novavax announced the signing of a non-binding memorandum of understanding (MoU) with the Ministry…
-
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
On May 21, 2021, AstraZeneca announced that it had been granted a special approval for emergency use in…
-
G20 leaders boosted support of the Access to COVID-19 Tools Accelerator
On May 21, 2021, world leaders the Global Health Summit adopted an agenda to overcome the COVID-19 pandemic,…
-
Japan’s Ministry of Health, Labour and Welfare approved Moderna’s COVID-19 vaccine
On May 21, 2021, Moderna announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan granted…
-
Complete trial results of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
-
Gavi signed agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX
On May 21, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Johnson…
-
Novavax announced participation in mix-and-match COVID-19 vaccine booster trial in the United Kingdom
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
-
Merck announced positive topline results from phase 3 pediatric studies for investigational 15-valent pneumococcal conjugate vaccine
On May 20, 2021, Merck announced V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity…
-
Pfizer and BioNTech announced supplying EU with up to 1.8 billion additional doses of COMIRNATY
On May 20, 2021, Pfizer and BioNTech announced a new agreement with the European Commission (EC) to supply…
-
Pfizer and BioNTech signed agreement to supply 60 million additional doses of their COVID-19 vaccine to Turkey
On May 20, 2021, Pfizer and BioNTech announced an agreement with Turkey’s Ministry of Health to supply 60…
-
Medicago and GSK announced positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
On May 18, 2021, GlaxoSmithKline and Medicago reported positive interim Phase 2 clinical trial safety and immunogenicity data for…
-
Sanofi and GSK COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in Phase 2 trial
On May 17, 2021, Sanofi and GSK reported that their adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates…
-
Preliminary data suggested mixing Covid-19 vaccine increases reactogenicity
On May 13, 2021, University of Oxford researchers reported that Com-COV study data comparing mixed dosing schedules of…
-
Moderna announced new supply agreement with Australia for 25 million doses of its COVID-19 vaccine
On May 12, 2021, Moderna announced a new supply agreement with the government of Australia for 25 million…
-
INOVIO’s Pan-COVID-19 vaccine candidate (INO-4802) induces broad immunity against vviral variants in preclinical studies
On May 12, 2021, Inovio Pharma announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies…
-
Novavax announced positive preclinical data for combination influenza and COVID-19 vaccine candidate
On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu…
-
INOVIO announced positive data from phase 2 clinical trial evaluating INO-4800 COVID-19 DNA vaccine
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
-
WHO listed additional COVID-19 vaccine for emergency use and issues interim policy recommendations
On May 7, 2021, the World Health Organization (WHO) listed the Sinopharm COVID-19 vaccine for emergency use, giving…
-
Pfizer and BioNTech initiated rolling submission of Biologics License Application for FDA approval of COVID-19 vaccine
On May 7, 2021, Pfizer and BioNTech announced the initiation of a Biologics License Application (BLA) with the…
-
Moderna announced agreement with Switzerland for 7 million booster vaccine doses in 2022 with options
On May 6, 2021, Moderna announced a new supply agreement with the Swiss Federal Government for 7 million…
-
Novavax and Gavi executed advance purchase agreement for COVID-19 vaccine for COVAX facility
On May 6, 2021, Novavax announced that it had finalized an advance purchase agreement (APA) with Gavi, the…
-
Pfizer and BioNTech announced supplying COVID-19 vaccine for Olympic athletes at 2020 Tokyo games
On May 6, 2021, Pfizer announced the signing of a Memorandum of Understanding (MoU) with the International Olympic…
-
NEJM published phase 2b clinical trial results demonstrating efficacy of COVID-19 vaccine against B.1.351 variant
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
-
Pfizer and BioNTech received Health Canada authorization of COVID-19 vaccine in adolescents
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
-
Moderna announced expansion of its manufacturing technology center in Massachusetts
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
-
Data from Vaxart oral COVID-19 vaccine phase I study suggested broad cross-reactivity against Coronaviruses
On May 3, 2021, Vaxart announced that new data obtained from its Phase I COVID-19 trial added to…
-
Moderna announced supply agreement with Gavi for up to 500 million doses of COVID-19 Vaccine Moderna for COVAX
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million…
